SMEDI Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 14, 2023 at 01:52 am EST
Share
SMEDI Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was KRW 954.39 million compared to KRW 766 million a year ago. Net loss was KRW 5,454.63 million compared to KRW 10,956.1 million a year ago. Basic loss per share from continuing operations was KRW 50 compared to KRW 127 a year ago. Basic loss per share was KRW 49 compared to KRW 127 a year ago.
For the nine months, sales was KRW 2,878.29 million compared to KRW 2,311.83 million a year ago. Net loss was KRW 3,310.72 million compared to KRW 30,291.76 million a year ago. Basic loss per share from continuing operations was KRW 35 compared to KRW 362 a year ago. Basic loss per share was KRW 36 compared to KRW 362 a year ago.
SMeDi Co Ltd, formerly The MediPharm Co Ltd, is a Korea-based company primarily engaged in the pharmaceutical distribution business. The Company operates through five segments. The Pharmaceuticals Business segment is engaged in the distribution of pharmaceuticals including recapsules and tablets. The Medical Business segment is engaged in the distribution of medical devices and medical supplies. The Wireless Device segment is engaged in the manufacture of wearable wireless devices. The Video Content segment is engaged in the production of video products. The Investment segment is engaged in the management consulting and investment businesses.
SMEDI CO., LTD. 
